One thousand and one nights of melatonin
PDF (Español (España))

Keywords

melatonin
oxidative stress
cancer
circadian rhythm

How to Cite

Saavedra-López, H. F. ., García-Pérez, M. J., & Arteaga-Díaz, J. M. . (2022). One thousand and one nights of melatonin. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 8(4). https://doi.org/10.53853/encr.8.4.725

Abstract

Background: Melatonin was first introduced in 1958 by dermatologist Aaron Lerner from a bovine pineal gland. Around 1970 was discovered its role in the regulation of the circadian rhythm and sleep-wake states, a role on which most clinical studies have focused. Its synthesis occurs from tryptophan through hydroxylation and acetylation processes,
later converted into melatonin. Since its discovery, multiple effects have been raised, all based on its effects as a regulator of oxidative stress; that is why clinical studies show that the supplementation of this hormone, in addition to regulating the circadian rhythm, has possible effects in the management of chronic non-communicable diseases
Objective: To report new evidence about the physiological and biochemical mechanisms of melatonin and discuss its possible therapeutic use.
Methodology: Literature review in the PubMed and Scopus database using the MeSH terms: “melatonin”; "circadian clocks"; "circadian rhythm"; "Cancer"; “oxidative stress”.
Results: There is great bibliographic evidence about the history of melatonin and its possible metabolic effects, which goes in line with its role as a regulator of the circadian rhythm, through the sleep-wake and light-dark states.
Conclusions: Melatonin can serve as an adjuvant in the management of chronic diseases such as cancer, obesity, fatty liver disease, mucositis and in the management of critically ill patients.

https://doi.org/10.53853/encr.8.4.725
PDF (Español (España))

References

Claustrat B, Leston J. Melatonin: Physiological effects in humans. Neurochirurgie. 2015;61(2-3):77-84. DOI: https://doi.org/10.1016/j.neuchi.2015.03.002

Illnait-Ferrer J. Melatonina: actualidad de una hormona olvidada Melatonin: the actuality of a forgotten hormone. Rev Cenic Cienc Biol. 2012;43(3).

Pérez-Beltrán CF, Díaz-Greene EJ, Rodríguez-Weber FL. Melatonina y su utilidad en la práctica diaria. Med Interna Mex. 2014;30(4).

Poza JJ, Pujol M, Ortega-Albás JJ, Romero O. Melatonin in sleep disorders. Neurol Engl Ed. 2020;36(9). DOI: https://doi.org/10.1016/j.nrleng.2018.08.004

Ganguly S, Coon SL, Klein DC. Control of melatonin synthesis in the mammalian pineal gland: the critical role of serotonin acetylation. Cell Tissue Res. 2002;309(1):127-37. DOI: https://doi.org/10.1007/s00441-002-0579-y

Amaral FG, Cipolla-Neto J. A brief review about melatonin, a pineal hormone. Arch Endocrinol Metab. 2018;62(4):472-9. DOI: https://doi.org/10.20945/2359-3997000000066

Bhattacharya S, Patel KK, Dehari D, Agrawal AK, Singh S. Melatonin and its ubiquitous anticancer effects. Mol Cell Biochem. 2019;462(1):133-55. DOI: https://doi.org/10.1007/s11010-019-03617-5

Cipolla-Neto J, Amaral FG. Melatonin as a hormone: new physiological and clinical insights. Endocr Rev. 2018;39(6):990-1028. DOI: https://doi.org/10.1210/er.2018-00084

Dacey DM, Liao HW, Peterson BB, Robinson FR, Smith VC, Pokorny J, et al. Melanopsin-expressing ganglion cells in primate retina signal colour and irradiance and project to the LGN. Nature. 2005;433(7027):749-54. DOI: https://doi.org/10.1038/nature03387

Freedman MS, Lucas RJ, Soni B, von Schantz M, Muñoz M, David-Gray Z, et al. Regulation of mammalian circadian behavior by non-rod, non-cone, ocular photoreceptors. Science. 1999;284(5413):502-4. DOI: https://doi.org/10.1126/science.284.5413.502

Zaidi FH, Hull JT, Peirson SN, Wulff K, Aeschbach D, Gooley JJ, et al. Short-wavelength light sensitivity of circadian, pupillary, and visual awareness in humans lacking an outer retina. Curr Biol. 2007;17(24):2122-8. DOI: https://doi.org/10.1016/j.cub.2007.11.034

Panda S, Provencio I, Tu DC, Pires SS, Rollag MD, Castrucci AM, et al. Melanopsin is required for non-image-forming photic responses in blind mice. Science. 2003;301(5632):525-7. DOI: https://doi.org/10.1126/science.1086179

Gooley JJ, Lu J, Fischer D, Saper CB. A broad role for melanopsin in nonvisual photoreception. J Neurosci. 2003;23(18):7093-106. DOI: https://doi.org/10.1523/JNEUROSCI.23-18-07093.2003

Hattar S, Liao HW, Takao M, Berson DM, Yau KW. Melanopsin-containing retinal ganglion cells: architecture, projections, and intrinsic photosensitivity. Science. 2002;295(5557):1065-70. DOI: https://doi.org/10.1126/science.1069609

Cajochen C, Jud C, Münch M, Kobialka S, Wirz?Justice A, Albrecht U. Evening exposure to blue light stimulates the expression of the clock gene PER2 in humans. Eur J Neurosci. 2006;23(4):1082-6. DOI: https://doi.org/10.1111/j.1460-9568.2006.04613.x

Acuña-Castroviejo D, Escames G, Venegas C, Díaz-Casado ME, Lima-Cabello E, López LC, et al. Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci. 2014;71(16):2997-3025. DOI: https://doi.org/10.1007/s00018-014-1579-2

Boutin JA, Jockers R. Melatonin controversies, an update. J Pineal Res. 2021;70(2):e12702. DOI: https://doi.org/10.1111/jpi.12702

Gamble KL, Berry R, Frank SJ, Young ME. Circadian clock control of endocrine factors. Nat Rev Endocrinol. 2014;10(8):466-75. DOI: https://doi.org/10.1038/nrendo.2014.78

Mohawk JA, Green CB, Takahashi JS. Central and peripheral circadian clocks in mammals. Annu Rev Neurosci. 2012;35:445-62. DOI: https://doi.org/10.1146/annurev-neuro-060909-153128

Harfmann BD, Schroder EA, Esser KA. Circadian rhythms, the molecular clock, and skeletal muscle. J Biol Rhythms. 2015;30(2):84-94. DOI: https://doi.org/10.1177/0748730414561638

Mason IC, Qian J, Adler GK, Scheer FA. Impact of circadian disruption on glucose metabolism: implications for type 2 diabetes. Diabetología. 2020;63(3):462-72. DOI: https://doi.org/10.1007/s00125-019-05059-6

Jagannath A, Taylor L, Wakaf Z, Vasudevan SR, Foster RG. The genetics of circadian rhythms, sleep and health. Hum Mol Genet. 2017;26(R2):R128-38. DOI: https://doi.org/10.1093/hmg/ddx240

Drew JE, Williams LM, Hannah LT, Barrett P, Abramovich DR, Morgan PJ. Melatonin receptors in the human fetal kidney: 2-(125I) iodomelatonin binding sites correlated with expression of Mel1a and Mel1b receptor genes. J Endocrinol. 1998;156(2):261-8. DOI: https://doi.org/10.1677/joe.0.1560261

Brydon L, Petit L, Delagrange P, Strosberg AD, Jockers R. Functional expression of MT2 (Mel1b) melatonin receptors in human PAZ6 adipocytes. Endocrinology. 2001;142(10):4264-71. DOI: https://doi.org/10.1210/endo.142.10.8423

Zibolka J, Bazwinsky?Wutschke I, Mühlbauer E, Peschke E. Distribution and density of melatonin receptors in human main pancreatic islet cell types. J Pineal Res. 2018;65(1):e12480. DOI: https://doi.org/10.1111/jpi.12480

Torres-Farfan C, Richter HG, Rojas-García P, Vergara M, Forcelledo ML, Valladares LE, et al. MT1 Melatonin receptor in the primate adrenal gland: inhibition of adrenocorticotropin-stimulated cortisol production by melatonin. J Clin Endocrinol Metab. 2003;88(1):450-8. DOI: https://doi.org/10.1210/jc.2002-021048

Dubocovich ML, Yun K, Al?Ghoul WM, Benloucif S, Masana MI. Selective MT2 melatonin receptor antagonists block melatonin?mediated phase advances of circadian rhythms. FASEB J. 1998;12(12):1211-20. DOI: https://doi.org/10.1096/fasebj.12.12.1211

Lewy AJ. Clinical applications of melatonin in circadian disorders. Dialogues Clin Neurosci. 2003;5(4):399. DOI: https://doi.org/10.31887/DCNS.2003.5.4/alewy

Lewy AJ, Ahmed S, Jackson JML, Sack RL. Melatonin shifts human orcadian rhythms according to a phase-response curve. Chronobiol Int. 1992;9(5):380-92. DOI: https://doi.org/10.3109/07420529209064550

Wajid F, Poolacherla R, Mim FK, Bangash A, Rutkofsky IH. Therapeutic potential of melatonin as a chronobiotic and cytoprotective agent in diabetes mellitus. J Diabetes Metab Disord. 2020;1-29. DOI: https://doi.org/10.1007/s40200-020-00585-2

Raygan F, Ostadmohammadi V, Bahmani F, Reiter RJ, Asemi Z. Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: a randomized, double-blind, placebo-controlled trial. Clin Nutr. 2019;38(1):191-6. DOI: https://doi.org/10.1016/j.clnu.2017.12.004

K?dziora?Kornatowska K, Szewczyk?Golec K, Kozakiewicz M, Pawluk H, Czuczejko J, Kornatowski T, et al. Melatonin improves oxidative stress parameters measured in the blood of elderly type 2 diabetic patients. J Pineal Res. 2009;46(3):333-7. DOI: https://doi.org/10.1111/j.1600-079X.2009.00666.x

Ortiz-Franco M, Planells E, Quintero B, Acuña-Castroviejo D, Rusanova I, Escames G, et al. Effect of melatonin supplementation on antioxidant status and DNA damage in high intensity trained athletes. Int J Sports Med. 2017;38(14):1117-25. DOI: https://doi.org/10.1055/s-0043-119881

Cardinali DP, Escames G, Acuña-Castroviejo D, Ortiz F, Fernández-Gil B, Guerra-Librero A, et al. Melatonin-induced oncostasis, mechanisms and clinical relevance. J Integr Oncol. 2016;S1(006):1-25. DOI: https://doi.org/10.4172/2329-6771.S1-006

Lauritzen ES, Kampmann U, Smedegaard SB, Støy J. Effects of daily administration of melatonin before bedtime on fasting insulin, glucose and insulin sensitivity in healthy adults and patients with metabolic diseases. A systematic review and meta?analysis. Clin Endocrinol (Oxf). 2021;95(5):691-701. DOI: https://doi.org/10.1111/cen.14576

Malaguarnera R, Ledda C, Filippello A, Frasca F, Francavilla VC, Ramaci T, et al. Thyroid Cancer and Circadian Clock Disruption. Cancers. 2020;12(11):3109. DOI: https://doi.org/10.3390/cancers12113109

Reiter RJ, Tan DX, Galano A. Melatonin: exceeding expectations. Physiology. 2014;29(5):325-33. DOI: https://doi.org/10.1152/physiol.00011.2014

Lozano A, Marruecos J, Rubió J, Farré N, Gómez-Millán J, Morera R, et al. Randomized placebo-controlled phase II trial of high-dose melatonin mucoadhesive oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing radiation therapy concurrent with systemic treatment. Clin Transl Oncol. 2021;23(9):1801-10. DOI: https://doi.org/10.1007/s12094-021-02586-w

Rayyan YM, Tayyem RF. Non-alcoholic fatty liver disease and associated dietary and lifestyle risk factors. Diabetes Metab Syndr Clin Res Rev. 2018;12(4):569-75. DOI: https://doi.org/10.1016/j.dsx.2018.03.016

Porter-Starr KN, Orenduff M, McDonald SR, Mulder H, Sloane R, Pieper CF, et al. Influence of weight reduction and enhanced protein intake on biomarkers of inflammation in older adults with obesity. J Nutr Gerontol Geriatr. 2019;38(1):33-49. DOI: https://doi.org/10.1080/21551197.2018.1564200

Szewczyk-Golec K, Rajewski P, Gackowski M, Mila-Kierzenkowska C, Weso?owski R, Sutkowy P, et al. Melatonin supplementation lowers oxidative stress and regulates adipokines in obese patients on a calorie-restricted diet. Oxid Med Cell Longev. 2017;2017. DOI: https://doi.org/10.1155/2017/8494107

Chojnacki C, Walecka-Kapica E, Klupinska G, Pawlowicz M, Blonska A, Chojnacki J. Effects of fluoxetine and melatonin on mood, sleep quality and body mass index in postmenopausal women. J Physiol Pharmacol. 2015;66(5):665-71.

Mansoori A, Salimi Z, Hosseini SA, Hormoznejad R, Jafarirad S, Bahrami M, et al. The effect of melatonin supplementation on liver indices in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized clinical trials. Complement Ther Med. 2020;52:102398. DOI: https://doi.org/10.1016/j.ctim.2020.102398

Bahrami M, Cheraghpour M, Jafarirad S, Alavinejad P, Asadi F, Hekmatdoost A, et al. The effect of melatonin on treatment of patients with non-alcoholic fatty liver disease: a randomized double blind clinical trial. Complement Ther Med. 2020;52:102452. DOI: https://doi.org/10.1016/j.ctim.2020.102452

Gandolfi JV, Di Bernardo APA, Chanes DAV, Martin DF, Joles VB, Amendola CP, et al. The effects of melatonin supplementation on sleep quality and assessment of the serum melatonin in ICU patients: A randomized controlled trial. Crit Care Med. 2020;48(12):e1286-93. DOI: https://doi.org/10.1097/CCM.0000000000004690

Khaing K, Nair BR. Melatonin for delirium prevention in hospitalized patients: A systematic review and meta-analysis. J Psychiatr Res. 2020;133:181-90. DOI: https://doi.org/10.1016/j.jpsychires.2020.12.020

Rodríguez-Rubio M, Figueira JC, Acuña-Castroviejo D, Borobia AM, Escames G, de la Oliva P. A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21(1):1-3. DOI: https://doi.org/10.1186/s13063-020-04632-4

Ziaei A, Davoodian P, Dadvand H, Safa O, Hassanipour S, Omidi M, et al. Evaluation of the efficacy and safety of Melatonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21(1):1-3. DOI: https://doi.org/10.1186/s13063-020-04737-w

Paul MA, Gray G, Kenny G, Pigeau RA. Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance. Aviat Space Environ Med. 2003;74(12):1263-70.

Suhner A, Schlagenhauf P, Tschopp A, Hauri-Bionda R, Friedrich-Koch A, Steffen R. Impact of melatonin on driving performance. J Travel Med. 1998;5(1):7-13. DOI: https://doi.org/10.1111/j.1708-8305.1998.tb00448.x

Andersen LP, Gögenur I, Rosenberg J, Reiter RJ. The safety of melatonin in humans. Clin Drug Investig. 2016;36(3):169-75. DOI: https://doi.org/10.1007/s40261-015-0368-5

Nordlund JJ, Lerner AB. The effects of oral melatonin on skin color and on the release of pituitary hormones. J Clin Endocrinol Metab. 1977;45(4):768-74. DOI: https://doi.org/10.1210/jcem-45-4-768

Shaw KM, Stern GM, Sandler M. Melatonin and parkinsonism. The Lancet. 1973;301(7797):271. DOI: https://doi.org/10.1016/S0140-6736(73)90118-9

Lyseng-Williamson KA. Melatonin prolonged release. Drugs Aging. 2012;29(11):911-23. DOI: https://doi.org/10.1007/s40266-012-0018-z

Invima. Listado de registros sanitarios vigentes de medicamentos con principio activo [Internet]. 2021. Disponible en: https://www.invima.gov.co/documents/20143/4033749/RS-MEDICAMENTOS-PAGINAWEB_VIGENTES+MAR+2021.pdf

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2021 Revista Colombiana de Endocrinología, Diabetes & Metabolismo

Downloads

Download data is not yet available.